Severe asthma guidelines: update 2019

Guidelines session
Chairs: F. Holguin (Aurora, United States of America), A. Bush (London, United Kingdom)
Aims: to review the role of biomarkers in treatment planning for severe asthma; to discuss the roles of new anti-type monoclonal antibodies in TH2-high asthma; to explore the treatment of non-eosinophilic asthma with specific reference to long-acting muscarinic agents and macrolides.

Link to guidelines

Clinical approach to very severe asthma and changes from the previous ERS-ATS task force J. Cardet (Tampa, United States of America)
The role of biomarkers in the management of severe asthma K. Chung (London, United Kingdom)
TH2-high asthma: a practical approach with cases and interactive questions P. Nair (Hamilton (ON), Canada)
Non-eosinophilic asthma: a practical approach with cases and interactive questions F. Schleich (Liège, Belgium)